Several oncology companies announced key trial milestones this week across the landscape of both blood cancers and solid ...

NEW YORK – Krystal Biotech has discontinued a Phase I/II clinical trial evaluating an injected version of its gene therapy KB707 in locally advanced or metastatic solid tumors, including melanoma.

Offering a modest gift card significantly increased enrollment of low-income individuals in a patient registry designed to ...

ALEX TORDOFF is relishing the prospect of fulfilling a lifelong dream as he saddles up for his Defender Burghley Horse Trials debut.

Vascular toxicity associated with cancer therapies is a leading cause of cardiovascular adverse events in patients with ...

NCX 470 0.1%, a novel nitric oxide-donating bimatoprost eye drop, achieved its primary endpoint in the phase 3 Denali ...

HBAR tests key support at $0.23 after a 3% pullback Friday, with resistance forming near $0.24. Bullish catalysts emerge as ...

Former Bahati Member of Parliament Kimani Ngunjiri has urged the swift prosecution of politicians implicated in corruption, ...

In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses clinical trial fail rates and AI’s ...

Kimberly (Cary) Demirhan, a registered nurse and assistant director of Education Programs at the Association of Cancer Care Centers (ACCC), sat down for an interview with CURE to discuss the need for ...

The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died ...

More than two years after the Food and Drug Administration held a public workshop on measuring overall survival (OS) in ...